Advancing LDL-C Control: Bridging Guideline Targets to Practice

Current European Society of Cardiology (ESC) guidelines advocate for increasingly stringent LDL-C targets based on individual cardiovascular risk stratification. For patients at very high cardiovascular risk, defined by established atherosclerotic cardiovascular disease (ASCVD), familial hypercholesterolaemia with ASCVD, or severe chronic kidney disease, an LDL-C target of less than 1.4 mmol/L (55 mg/dL) and a reduction of at least 50% from baseline is recommended. For high-risk patients, the target is less than 1.8 mmol/L (70 mg/dL), also with a 50% reduction. These targets are supported by extensive evidence demonstrating a continuous, graded relationship between lower LDL-C levels and reduced cardiovascular event rates. Despite these clear recommendations, real-world observational studies consistently show that a considerable number of patients do not achieve these therapeutic goals. This discrepancy suggests that factors beyond drug efficacy, such as adherence, therapeutic inertia, and patient-specific challenges, contribute to the suboptimal control observed in clinical practice.

Addressing the Treatment Gap

The primary therapeutic strategy for LDL-C reduction involves statins, which are highly effective and well-tolerated. However, many patients require additional lipid-lowering agents to reach their target LDL-C levels, especially those at high and very high risk. Ezetimibe, a cholesterol absorption inhibitor, provides an incremental reduction in LDL-C of approximately 15-20% when added to statin therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as evolocumab and alirocumab, offer substantial additional LDL-C lowering, typically around 50-60%, when used in combination with statins, or as monotherapy in statin-intolerant patients. These agents have demonstrated significant reductions in major adverse cardiovascular events (MACE) in large-scale clinical trials. Despite the availability of these potent therapies, their uptake and appropriate utilisation in clinical practice remain suboptimal. Data from various registries indicate that less than 50% of very high-risk patients achieve their guideline-recommended LDL-C targets, even with statin therapy. The proportion achieving targets with combination therapy, including PCSK9 inhibitors, is even lower. This suggests a need for improved implementation strategies, enhanced patient education, and more proactive therapeutic intensification by clinicians.

Several factors contribute to the observed treatment gap. Therapeutic inertia, defined as the failure of healthcare providers to initiate or intensify therapy when indicated, is a significant barrier. This can stem from various reasons, including concerns about polypharmacy, potential side effects, patient preference, or a lack of awareness regarding the latest guideline recommendations. Patient adherence to prescribed medications is another critical factor. Poor adherence, often due to complex dosing regimens, perceived side effects, or cost, can significantly compromise treatment effectiveness. Furthermore, the under-recognition of high-risk patient populations and the underestimation of their individual LDL-C goals can lead to insufficient treatment. For instance, patients with diabetes, chronic kidney disease, or a history of premature ASCVD are often not managed to the same aggressive LDL-C targets as those with established ASCVD, despite their elevated risk.

Future strategies to advance LDL-C control must focus on systematic approaches to identify high-risk patients, overcome therapeutic inertia, and improve patient adherence. This includes the implementation of clinical decision support systems, regular audits of LDL-C control rates, and multidisciplinary team approaches. Educational initiatives targeting both clinicians and patients are essential to raise awareness of guideline targets and the benefits of intensive lipid-lowering therapy. The integration of novel therapies, such as inclisiran, a small interfering RNA (siRNA) targeting PCSK9, which offers sustained LDL-C reduction with twice-yearly dosing, may also help address adherence challenges and improve long-term control. However, the successful integration of such therapies into routine practice will depend on clear prescribing pathways, appropriate patient selection, and cost-effectiveness considerations.